Novel Mycobacterium tuberculosis compounds for MDR-TB treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) are lengthy, associated with significant side effects, and often lead to poor patient compliance, further exacerbating drug resistance.
Innovation Solution
Development of novel compounds, specifically those of Formula Ia, Ib, II, and III, which are effective against MDR-TB and XDR-TB, while also being non-cytotoxic and potentially useful in treating drug-sensitive tuberculosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current first line agents (rifampicin, isoniazid, ethambutol, pyrazinamide) are used for TB treatment, then the treatment is curable, but the development of antibiotic resistance poses a major threat and treatment duration is lengthy
Solution Approach 1:
The patent changes the chemical parameters of the treatment agents by synthesizing novel compounds with modified molecular structures. These compounds have different chemical properties that allow them to act more effectively against MDR-TB and XDR-TB strains, enabling shorter treatment durations while maintaining curability. The parameter changes occur at the molecular level, creating agents that overcome drug resistance mechanisms.
Solution Approach 2:
The invention creates composite therapeutic approaches by combining multiple novel compounds with different mechanisms of action. These composite treatments target multiple bacterial processes simultaneously (cell wall synthesis, DNA replication, protein synthesis), thereby reducing the duration required to achieve cure while preventing resistance development through multi-target inhibition.
2Reliability
If second line drugs including fluoroquinolones and injectable aminoglycosides are added for MDR-TB treatment, then resistance to first line agents is overcome, but the emergence of extensively drug-resistant TB increases and side effects increase
Solution Approach 1:
The patent develops novel compounds that act as single-use, high-efficacy agents against specific resistance patterns. These compounds are designed to be used in limited, targeted scenarios (MDR-TB and XDR-TB treatment) rather than as part of a long-term combination regimen, thereby reducing overall exposure to multiple drugs with different side effect profiles and minimizing the selection pressure that leads to further resistance emergence.
Solution Approach 2:
The invention modifies the pharmacological parameters of the treatment agents by creating compounds with altered chemical structures that confer selective pressure against specific resistance mechanisms. This allows for targeted effective treatment of MDR-TB and XDR-TB while avoiding the need to combine multiple agents with different toxicity profiles, thereby reducing overall harmful effects.
3Reliability
If combination therapy with multiple agents is used for MDR-TB and XDR-TB, then drug resistance is addressed, but patient compliance decreases due to lengthy treatment and side effects
Solution Approach 1:
The patent segments the treatment approach by developing a series of novel compounds, each targeting specific resistance patterns or bacterial processes. This segmentation allows for a more streamlined treatment regimen where patients receive targeted therapy rather than complex multi-agent combination therapy, thereby improving compliance while maintaining effectiveness against drug-resistant strains.
Solution Approach 2:
The invention changes the pharmacokinetic and pharmacodynamic parameters of the treatment agents to achieve faster bacterial killing and shorter treatment durations. By modifying the chemical structures to improve cellular penetration and metabolic stability, the compounds can achieve effective concentrations faster, reducing the overall treatment time and improving patient compliance.
4Reliability
If pretomanid combination therapy is used for XDR-TB, then treatment effectiveness is strengthened, but the treatment is reserved for few cases and resistance to bedaquiline and delamanid has already emerged
Solution Approach 1:
The patent creates a universal platform of novel compounds that can be applied across different TB case types (drug-sensitive, MDR-TB, and XDR-TB) by modifying the chemical structures to target specific resistance patterns. This multi-functionality allows the same compound class to be used in various treatment scenarios, improving adaptability while maintaining high effectiveness against XDR-TB strains.
Data Source
AI summary
In one aspect, the disclosure relates to compounds effective in the treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis as well as drug-sensitive tuberculosis, methods of making the same, pharmaceutical compositions comprising the same, and methods of treating bacterial infections caused by Mycobacterium tuberculosis using the same. In an aspect, the compounds and pharmaceutical compositions are not cytotoxic. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.